BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia. Robert F, Badja C, Boushaki S, Degasperi A, et al. Ann Hematol 2026;105:32.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Robert F, Badja C, Boushaki S, Degasperi A, et al. BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia. Ann Hematol 2026;105:32.
PMID: 41549155